ERVIN GRAVES STRATEGY GROUP, LLC for EMERGENT BIOSOLUTIONS INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24 and FY25; Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines; NDAA for Fiscal Year 2024 and Fiscal Year 2025 - provisions related to biological and chemical defense and access to naloxone; FAA reauthorization - increasing access to naloxone.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES L ERVIN | — |
| MATTHEW MARSH | — |
| DANIEL SAUERS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.